MiMedx announces Wound & Surgical product pipeline expansion

MiMedx Group announced that it has licensed worldwide exclusive rights to Turn Therapeutics’ proprietary antimicrobial technology platform, PermaFusion, for the development of future biologic products focused on wound and surgical recovery applications. "Today’s transaction enables a meaningful expansion of our product development pipeline ambitions," stated Todd Newton, MIMEDX interim Chief Executive Officer. "This deal allows us to bring new amniotic tissue and particulate products to market with antimicrobial properties significantly faster, consistent with our stated goal of ensuring that our R&D activities are prioritized, productive and pursued with a sense of urgency. Putting together Turn’s intellectual property with our tissue know-how will help us leapfrog into the next generation of biologics for our Wound & Surgical business." PermaFusion is petrolatum-based, liquid-in-oil suspension technology that involves the creation of nanodroplets without binding agents or emulsifiers and also includes a process to coat materials with antimicrobial-infused petrolatum. In addition to the exclusive license to Turn’s IP, MIMEDX is acquiring the commercial rights to Turn’s particulate collagen matrix product, Fle AM, contingent upon its receipt of FDA 510(k) clearance, which is expected in 2023. Under the terms of the agreement, MIMEDX has exclusive rights to develop future products for the wound care, burn, and surgical fields using Turn’s IP.